Metformin and anti‐inflammatory medication use associated with reduced delirium risk and all‐cause mortality

DOI
  • Yamanashi Takehiko
    Tottori University Hospital, Department of Psychiatry
  • Shinozaki Gen
    Stanford University School of Medicine Department of Psychiatry and Behavioral Sciences

Bibliographic Information

Other Title
  • 新しいせん妄予防法の検証〜メトホルミンと抗炎症薬を中心に〜

Abstract

Novel approaches to prevent delirium are needed. Metformin has been reported to improve age‐related disorders, including dementia, and to lower mortality. Furthermore, anti‐inflammatory drugs attenuate inflammation, which is thought to be a risk of delirium. Thus, we hypothesized that metformin or anti‐inflammatory drug exposure would be associated with reduced prevalence of delirium and lower risk of mortality. We conducted retrospective cohort studies using data from our previous studies. It was found that a history of metformin use reduced the risk of delirium and the risk of 3‐year mortality in patients with a type 2 diabetes mellitus. It was also found that a history of NSAIDs use tended to reduce the risk of delirium and decreased risk of one‐year mortality. These data showed the potential benefit of metformin and NSAIDs on delirium risk and mortality.

Journal

Keywords

Details 詳細情報について

  • CRID
    1390299595850361728
  • DOI
    10.11249/jsbpjjpp.35.1_29
  • ISSN
    21866465
    21866619
  • Text Lang
    ja
  • Data Source
    • JaLC
  • Abstract License Flag
    Disallowed

Report a problem

Back to top